Navigation Links
Transient receptor potential channel A1 may contribute to hyperalgesia
Date:12/23/2013

Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia. However, there is no direct evidence that activation of transient receptor potential channel A1 contributes to neuropeptide release from primary afferent neurons. A recent study by Yi Dai and team from Hyogo College of Medicine in Japan demonstrated for the first time that allyl isothiocyanate (AITC; also known as mustard oil) activates transient receptor potential channel A1, resulting in calcitonin gene-related peptide release from the cultured rat dorsal root ganglion neurons. Knockdown of transient receptor potential channel A1 with an antisense oligodeoxynucleotide prevented calcitonin gene-related peptide release by allyl isothiocyanate application in cultured dorsal root ganglion neurons. Thus, the researchers concluded that transient receptor potential channel A1 activation caused calcitonin gene-related peptide release in sensory neurons. These findings were published in the Neural Regeneration Research (Vol. 8, No. 32, 2013).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related biology news :

1. Stanford and Google team up to simulate key drug receptor
2. Extensive variability in olfactory receptors influences human odor perception
3. Researchers use nanoscale patches to sensitize targeted cell receptors
4. New book on Signaling by Receptor Tyrosine Kinases by Cold Spring Harbor Laboratory Press
5. Dysfunctional chemokine receptor promotes candidiasis
6. Baculovirus-recognizing human cell receptor identified for the first time
7. Blocking overactive receptor in Alzheimers recovers memory loss and more
8. OHSU scientists advance understanding of brain receptor; may help fight neurological disorders
9. Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
10. Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
11. Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transient receptor potential channel A1 may contribute to hyperalgesia
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: